Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18648
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsao, Simon Chang-Hao-
dc.contributor.authorWeiss, Jonathan-
dc.contributor.authorHudson, Christopher-
dc.contributor.authorChristophi, Christopher-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorBehren, Andreas-
dc.contributor.authorDobrovic, Alexander-
dc.date2015-06-22-
dc.date.accessioned2018-08-30T06:34:05Z-
dc.date.available2018-08-30T06:34:05Z-
dc.date.issued2015-06-22-
dc.identifier.citationScientific Reports 2015; 5: 11198-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18648-
dc.description.abstractWe assessed the utility of droplet digital PCR (ddPCR) to evaluate the potential of using circulating tumour DNA (ctDNA) as a post therapy monitoring tool in melanoma by comparing it to serum LDH levels and RECIST scores. ddPCR was shown to be reliable in distinguishing mutant from wild type alleles with no false positives. Subsequently, we quantified ctDNA ((V600E)BRAF,(V600K)BRAF or (Q61H)NRAS) in 6 stage IV melanoma patients across several time points during their treatment course. All tested patients had detectable ctDNA, which exhibited dynamic changes corresponding to the changes in their disease status. The ctDNA levels fell upon treatment response and rose with detectable disease progression. In our group of patients, ctDNA was more consistent and informative than LDH as a blood-based biomarker. In addition, BRAF mutant ctDNA as detected by ddPCR could be used diagnostically where the tumour block was unavailable. In conclusion, this study demonstrates the applicability of using ddPCR to detect and quantify ctDNA in the plasma of melanoma patients.-
dc.language.isoeng-
dc.titleMonitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.-
dc.typeJournal Article-
dc.identifier.journaltitleScientific Reports-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Pathology, University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia-
dc.identifier.doi10.1038/srep11198-
dc.identifier.orcid0000-0001-5329-280Xen
dc.identifier.orcid0000-0002-3898-950Xen
dc.identifier.orcid0000-0003-3414-112Xen
dc.identifier.pubmedid26095797-
dc.type.austinJournal Article-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherCebon, Jonathan S
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptSurgery-
crisitem.author.deptHepatopancreatobiliary Surgery-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Jun 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.